EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Chemoradiotherapy with versus without concurrent immune checkpoint inhibitor for locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study

Jiang-Qiong Huang, Hui-Min Xiao, Cheng-Xian Ma, Run-Zhi Wang, Huan-Wei Liang, Wei Huang, Xin-Bin Pan iD

Diseases of the Esophagus · 09.01.2026 · 39 (1)

DOI: 10.1093/dote/doag007 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diseases of the Esophagus, online erschienen am 02.02.2026. Verfasst von Jiang-Qiong Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, P.R. China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Esophageal Neoplasms, Chemoradiotherapy, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To compare survival outcomes and safety between concurrent chemoradiotherapy (CCRT) and CCRT with concurrent immune checkpoint inhibitor (ICI) in patients with locally advanced esophageal squamous cell carcinoma. This multicenter cohort study enrolled consecutive patients treated between January 2010 and April 2024. Patients were stratified into two groups: CCRT and CCRT+ICI. Of 290 eligible patients, 64 received CCRT+ICI and 226 received CCRT. CCRT followed by ICI maintenance therapy improved disease-free survival compared to CCRT+ICI (hazard ratio [HR] = 2.33, 95% CI: 1.04-5.24; P = 0.040), although it did not improve overall survival (HR = 1.12, 95% CI: 0.45-2.81; P = 0.804). Disease-free survival (HR = 1.25, 95% CI: 0.72-2.16; P = 0.428) and overall survival (HR = 0.94, 95% CI: 0.46-1.93; P = 0.861) were comparable between CCRT alone and CCRT+ICI groups. CCRT+ICI had a higher incidence of grade ≥ 3 leukopenia and neutropenia. Following CCRT, median lymphocyte counts decreased in both CCRT+ICI (1.30 versus 0.35) and CCRT (1.57 versus 0.30) groups. In contrast, monocyte counts increased in the CCRT+ICI group (0.33 versus 0.49), but remained stable in the CCRT group (0.50 versus 0.49). CCRT with concurrent ICI failed to improve survival in patients with locally advanced esophageal squamous cell carcinoma, potentially due to CCRT induced immunosuppression. In contrast, CCRT followed by ICI maintenance therapy showed promise in improving disease-free survival, suggesting that the timing of immunotherapy integration is critical for therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsEsophageal NeoplasmsChemoradiotherapyEsophageal Squamous Cell CarcinomaHumansRetrospective StudiesMaleFemaleMiddle AgedAgedDisease-Free SurvivalTreatment OutcomeLeukopenia

Stichwörter der Autor:innen

chemotherapyesophageal cancerimmune checkpoint inhibitorradiotherapysurvival

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, P.R. China.
  • Department of Oncology, Rui-Kang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, P.R. China.

ORCID-Profile: Xin-Bin Pan

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangxi China
  • China Postdoctoral Science Foundation

Zitieren

APA

Huang, J. Q., Xiao, H. M., Ma, C. X., Wang, R. Z., Liang, H. W., Huang, W., & Pan, X. B. (2026). Chemoradiotherapy with versus without concurrent immune checkpoint inhibitor for locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study. Diseases of the Esophagus, 39(1). https://doi.org/10.1093/dote/doag007

Vancouver

Huang JQ, Xiao HM, Ma CX, Wang RZ, Liang HW, Huang W, et al. Chemoradiotherapy with versus without concurrent immune checkpoint inhibitor for locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study. Diseases of the Esophagus. 2026;39(1). doi:10.1093/dote/doag007

BibTeX
@article{Huang2026,
  author = {Huang, Jiang-Qiong and Xiao, Hui-Min and Ma, Cheng-Xian and Wang, Run-Zhi and Liang, Huan-Wei and Huang, Wei and Pan, Xin-Bin},
  title = {Chemoradiotherapy with versus without concurrent immune checkpoint inhibitor for locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study},
  journal = {Diseases of the Esophagus},
  year = {2026},
  volume = {39},
  number = {1},
  doi = {10.1093/dote/doag007}
}
Kostenlos starten →